0000000000320764

AUTHOR

Paolo Caruso

showing 3 related works from this author

Adherence to biological therapy in dermatological patients during the COVID‐19 pandemic in Western Sicily

2020

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)business.industrySkin DiseaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINECOVID-19DermatologySkin DiseasesVirologyMedication AdherenceBiological TherapyCommunicable Disease ControlEpidemiologyPandemicmedicineHumansbusinessSicilyHumanInternational Journal of Dermatology
researchProduct

Our experience with prurigo nodularis treated with dupilumab.

2020

medicine.medical_specialtyprurigo nodularibusiness.industryPruritusMEDLINEDermatologyDupilumabmedicine.diseaseAntibodies Monoclonal HumanizedDupilumabDermatologyInfectious DiseasesMedicineHumansPrurigobusinessNeurodermatitisPrurigo nodularisNeurodermatitisJournal of the European Academy of Dermatology and Venereology : JEADV
researchProduct

Timing of quality of life improvements in psoriatic patients treated with different systemic therapies

2019

Psoriasis impacts the quality of life (QoL) by disrupting overall health and social life. Thus, the use of a QoL evaluation item is crucial in assessing a therapeutic regimen. Also, faster improvements in QoL lead to better patient compliance, but very few studies compare psoriasis traditional and biologic therapies timing. To evaluate how much different systemic therapies improve disease severity and QoL, a retrospective analysis was performed on 56 patients. Subjects were administered different drugs and their vital statistics, psoriasis area severity index (PASI) and PSOdisk were collected at baseline and after 30 days. We found a moderate correlation between PASI and PSOdisk score with …

AdultMalemedicine.medical_specialtyTime FactorsAdolescentAnti-Inflammatory AgentsDermatologySeverity of Illness IndexSocial lifeYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineDisease severityQuality of lifeSurveys and QuestionnairesPsoriasisInternal medicinesystemic therapiesUstekinumabmedicineHumansPsoriasisPatient complianceAgedRetrospective StudiesSkinpsoriasiAged 80 and overTherapeutic regimenbusiness.industryBiologic therapiesAdalimumabGeneral MedicineMiddle Agedmedicine.diseasehumanitiesBiological TherapyTreatment Outcomequality of life030220 oncology & carcinogenesisCyclosporineFemaleUstekinumabDermatologic AgentsbusinessFollow-Up Studiesmedicine.drug
researchProduct